We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Reports Positive Phase II Data on Migraine Drug
Read MoreHide Full Article
Novartis AG (NVS - Free Report) announced results from a phase II study on migraine candidate AMG334.
Data from the study were presented at the fifth European Headache and Migraine Trust International Congress (EHMTIC) in Glasgow, Scotland.
The study enrolled 667 patients who had a mean baseline of approximately 18 migraine days per month. The study showed that AMG334 led to a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine.
Moreover, a significantly higher number of patients receiving monthly subcutaneous administration of AMG334 70mg or 140mg, experienced a reduction of 50% or more in the number of monthly migraine days, compared with placebo.
We note that Novartis is developing AMG334 in collaboration with Amgen, Inc. (AMGN - Free Report) . Under the collaboration agreement dated 2015, the companies agreed to jointly develop and commercialize treatments in the field of Alzheimer's disease and migraine. Amgen retained commercialization rights for AMG334 in the U.S., Canada and Japan, while Novartis owns the rights to Europe and the rest of world.
Meanwhile, Novartis expects results from phase III studies on AMG 334 in episodic migraine later this year.
Another migraine candidate being developed under this collaboration is AMG301 (currently in a phase I study).
We expect investors to keep an eye on the approval of new drugs and label expansion of existing ones at Novartis, given that the company has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Novartis Reports Positive Phase II Data on Migraine Drug
Novartis AG (NVS - Free Report) announced results from a phase II study on migraine candidate AMG334.
Data from the study were presented at the fifth European Headache and Migraine Trust International Congress (EHMTIC) in Glasgow, Scotland.
The study enrolled 667 patients who had a mean baseline of approximately 18 migraine days per month. The study showed that AMG334 led to a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine.
NOVARTIS AG-ADR Price and Consensus
NOVARTIS AG-ADR Price and Consensus | NOVARTIS AG-ADR Quote
Moreover, a significantly higher number of patients receiving monthly subcutaneous administration of AMG334 70mg or 140mg, experienced a reduction of 50% or more in the number of monthly migraine days, compared with placebo.
We note that Novartis is developing AMG334 in collaboration with Amgen, Inc. (AMGN - Free Report) . Under the collaboration agreement dated 2015, the companies agreed to jointly develop and commercialize treatments in the field of Alzheimer's disease and migraine. Amgen retained commercialization rights for AMG334 in the U.S., Canada and Japan, while Novartis owns the rights to Europe and the rest of world.
Meanwhile, Novartis expects results from phase III studies on AMG 334 in episodic migraine later this year.
Another migraine candidate being developed under this collaboration is AMG301 (currently in a phase I study).
We expect investors to keep an eye on the approval of new drugs and label expansion of existing ones at Novartis, given that the company has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec.
Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Ligand Pharmaceuticals (LGND - Free Report) and Pacira Pharmaceuticals (PCRX - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>